Suppr超能文献

印度浦那一线抗逆转录病毒治疗免费 ART 项目门诊的使用情况——初步报告。

Use of first line antiretroviral therapy from a free ART programme clinic in Pune, India - a preliminary report.

机构信息

National AIDS Research Institute (ICMR), Pune, India.

出版信息

Indian J Med Res. 2013 May;137(5):942-9.

Abstract

BACKGROUND & OBJECTIVES: The treatment outcomes under national antiretroviral therapy (ART) programme are being evaluated in some ART centres in the country. We carried out this study to analyze the impact of first line antiretroviral therapy in HIV infected patients attending a free ART roll out national programme clinic in Pune, India.

METHODS

Antiretroviral naive HIV infected patients attending the clinic between December 2005 and April 2008 and followed up till March 31, 2011 were included in the analysis. The enrolment and follow up of these patients were done as per the national guidelines. Viral load estimations were done in a subset of patients. results: One hundred and forty two patients with median CD4 count of 109 cells/μl (IQR: 60-160) were initiated on treatment. The median follow up was 44 months (IQR: 37-53.3 months). Survival analysis showed that the probability of being alive at the end of 5 years was 85 per cent. Overall increase in the median CD4 count was statistically significant (P<0.001). It was significant in patients with >95 per cent adherence (P<0.001). In 14 per cent patients, the absolute CD4 count did not increase by 100 or more cells/μl at the end of 12 months. Viral load estimation in a subset of 68 patients showed undetectable levels in 61 (89.7%) patients after a median duration of 46 months (IQR: 38.3-54.8).

INTERPRETATION & CONCLUSIONS: The first line treatment was effective in patients attending the programme clinic. The adherence level influenced immunological and virological outcomes of patients.

摘要

背景与目的

在一些国家的抗逆转录病毒治疗(ART)中心正在评估国家抗逆转录病毒治疗方案的治疗效果。我们开展了这项研究,以分析在印度浦那的一个免费抗逆转录病毒治疗铺开国家方案诊所接受治疗的艾滋病毒感染者的一线抗逆转录病毒治疗的影响。

方法

纳入 2005 年 12 月至 2008 年 4 月期间在诊所就诊且随访至 2011 年 3 月 31 日的初治抗逆转录病毒的 HIV 感染者。这些患者的登记和随访是按照国家指南进行的。对部分患者进行了病毒载量检测。结果:142 名 CD4 计数中位数为 109 个细胞/μl(IQR:60-160)的患者开始接受治疗。中位随访时间为 44 个月(IQR:37-53.3 个月)。生存分析显示,5 年后存活的概率为 85%。总的来说,CD4 计数中位数的增加具有统计学意义(P<0.001)。在 95%以上依从性的患者中更为显著(P<0.001)。在 14%的患者中,12 个月后绝对 CD4 计数没有增加 100 个或更多细胞/μl。在 68 名患者中进行了病毒载量检测,中位随访 46 个月(IQR:38.3-54.8)后,61 名(89.7%)患者病毒载量不可测。

解释与结论

方案诊所的一线治疗对患者有效。依从水平影响了患者的免疫和病毒学结局。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47bd/3734687/352a1e4ae39c/IJMR-137-942-g002.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验